AT ATG+ SIKLOFOSFAMID PROTOKOLÜ

Kaynaklar:

1-Kang, H. J., H. Y. Shin, J. E. Park, et al. 2010. "Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study." Biol Blood Marrow Transplant 16(11):1582-1588.

2-Kekre, N., Y. Zhang, M. J. Zhang, et al. 2017. "Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia." Haematologica 102(7):1291-1298.

3-Bhurani, D., M. Schifter and I. Kerridge. 2008. "Folinic acid administration following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand." Bone Marrow Transplant 42(8):547-550.

4-Bacigalupo, A., G. Socie, E. Lanino, et al. 2010. "Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party." Haematologica 95(6):976-982.

5-Bressler RB and Huston DP 1985. "Water intoxication following moderate-dose intravenous cyclophosphamide." Arch Intern Med Mar;145(3):548-9.

6-Locatelli, F., B. Bruno, M. Zecca, et al. 2000. "Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial." Blood 96(5):1690-1697.

7-Ades, L, J. Y. Mary, M. Robin, et al. 2004. "Long-term outcome after bone marrow transplantation for severe aplastic anemia." Blood 103(7):2490-2497.